Development of mRNA Vaccines in Felines
Both kittens and adult cats are vulnerable to a number of infections. New advances in veterinary medicine have increased the number of vaccines that are available for cats. The safety and efficacy of vaccines are also improving. Veterinarians often recommend certain vaccinations (called core vaccines) for all cats.
Core vaccines for cats recommended by the American Association of Feline Practitioners (AAFP) include the following:
- Vaccine against Feline Leukopenia Virus (FPV), which is a highly infectious and potentially fatal virus that causes fever, vomiting, diarrhea, loss of appetite, and in some cases, sudden death in cats.
- Vaccine for Feline Rhinotracheitis Virus (FRV), or Feline Herpesvirus (FHV), that can result in upper respiratory infection with fever, sneezing, eye and nasal discharge, conjunctivitis, keratitis, and lethargy.
- Vaccine for Feline Calicivirus (FCV), one of the main causes of upper respiratory infection in cats and can be deadly in as many as half of affected cats as a severe form of calicivirus, it.
- Vaccine for Rabies Virus, which is a fatal viral infection provided by contacting with the saliva of an infected animal through a bite or open wound. Humans are at risk for rabies virus infection.
- Vaccine against Feline Leukemia Virus (FeLV), which is a major cause of virus-associated deaths of cats and FeLV vaccination is considered a core vaccine for kittens.
The three core feline vaccines (FPV, FRV and FCV) have been combined into a triple vaccine called the FVRCP vaccine.
Marketed FVRCP vaccines are predominantly based on viral cultures. mRNA vaccines are produced using a chemically defined and consistent process, with the potential to simplify vaccine production, scale-up, quality control, and the overall vaccine development timeline. Several FVRCP-containing mRNA vaccines (FPV, FRV, and FCV) are in development.
Yaohai Bio-Pharma Offers One-Stop Solution for RNA
Custom Deliverables
|
Grade
|
Deliverables
|
Specification
|
Applications
|
|
non-GMP
|
Drug Substance, mRNA
|
0.1~10 mg (mRNA)
|
Preclinical research such as cell transfection, Analytical method development, Pre-stability studies, Formulation development
|
|
Drug Product, LNP-mRNA
|
|
GMP
|
Drug Substance, mRNA
|
10 mg~70 g
|
Investigational new drug (IND), Clinical trial authorisation (CTA), Clinical trial supply, Biologic license application (BLA), Commercial supply
|
|
Drug Product, LNP-mRNA
|
5000 vials or pre-filled syringes/ cartridges
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
